Species bcr-abl kinase inhibitor

The present invention relates to a kind of BCR-ABL kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof, wherein R, R, R, R, R, R as defined in the specification. Compounds of the invention also relates to pharmaceutical compositions comprising a compound of formula I of the present invention and by the BCR-ABL kinase mediated through activation of a medicament for treating a disorder in a mammal.